Literature DB >> 3930407

In vitro activity of ceftazidime in combination with other antibiotics.

C Simon, G Littschwager.   

Abstract

189 bacterial strains were investigated for their in vitro sensitivity against ceftazidime (alone and in combination with another antibiotic). Moreover, the possibility to prevent development of secondary bacterial resistance as observed in subcultures at subinhibitory antibiotic concentrations, was studied using specific antibiotic combinations. Of 115 staphylococcal strains (91 strains of Staphylococcus aureus, 24 strains of Staphylococcus epidermidis), 2% were sensitive, 82% were moderately sensitive and 16% were resistant to ceftazidime. On combining ceftazidime with vancomycin, synergism was found in 61% of the strains, and secondary resistance to ceftazidime could be prevented with this combination. The combination of ceftazidime and clindamycin showed synergism in 26% and an additive effect in 48% of the strains. Secondary resistance to ceftazidime did not develop with this combination in subcultures at subinhibitory concentrations in which loss of activity was only minimal with clindamycin alone. Rifampicin and fusidic acid were highly active against staphylococci. In combination with ceftazidime, only weak synergism or additive effects were seen in most strains; no antagonism could be observed. In subcultures at subinhibitory concentrations, secondary resistance to rifampicin and fusidic acid developed rapidly and could be partially prevented by adding ceftazidime. Of 60 Pseudomonas aeruginosa strains, 84% were sensitive, 13% were moderately sensitive and 2% were resistant to ceftazidime. Synergism was most frequently observed when ceftazidime was combined with tobramycin. Using this combination, secondary resistance of Pseudomonas strains to ceftazidime did not develop. When ceftazidime was combined with piperacillin, synergism was observed in most strains, but the development of secondary resistance in vitro was not prevented.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930407     DOI: 10.1007/bf01642810

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

1.  [Has the rate of resistant staphylococci increased recently? (author's transl)].

Authors:  K H Spitzy; M Rotter
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  Ceftazidime: a questionable alternative to the aminoglycosides.

Authors:  J Roos
Journal:  Lancet       Date:  1982-09-04       Impact factor: 79.321

3.  [On the combination of clindamycin with beta-lactam antibiotics and aminoglycosides (author's transl)].

Authors:  D Adam; I Nawrath
Journal:  Arzneimittelforschung       Date:  1981

4.  Studies on multi-antibiotic resistant strains of Staphylococcus aureus.

Authors:  H Chmel; A Person; F Tecson-Tumang
Journal:  Infection       Date:  1982       Impact factor: 3.553

5.  The activity of ceftazidime, other beta-lactams, and aminoglycosides against Pseudomonas aeruginosa.

Authors:  K V Rolston; P H Chandrasekar; J L LeFrock; R F Schell
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

6.  Combination of minocycline and rifampicin against methicillin- and gentamicin-resistant Staphylococcus aureus.

Authors:  E Yourassowsky; M P van der Linden; M J Lismont; F Crokaert
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

7.  Reduced sensitivity to beta-lactam antibiotics arising during ceftazidime treatment of Pseudomonas aeruginosa infections.

Authors:  A King; K Shannon; S Eykyn; I Phillips
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

8.  [Monotherapy of systematic Pseudomonas aeruginosa infections with ceftazidime. The causes of therapeutic failures].

Authors:  J Blaser; A Bauernfeind; M Vogt; R Lüthy
Journal:  Dtsch Med Wochenschr       Date:  1983-09-02       Impact factor: 0.628

9.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

Review 10.  Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Clinical data on 650 patients (a review).

Authors:  M Kissling; N Bergamini
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

View more
  2 in total

1.  Macular infarction after intravitreal amikacin: authors' reply.

Authors:  G D Galloway; A Ramsay; K Jordan; A Vivian
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

2.  Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers.

Authors:  M Boeckh; H Lode; K Borner; G Höffken; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.